Free Trial

Humana (HUM) Stock Forecast & Price Target

→ Wall Street Legend Warns: 'A Strange Day Is Coming to America' (From Chaikin Analytics) (Ad)
Free HUM Stock Alerts
$349.21
-0.09 (-0.03%)
(As of 05/28/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends

Humana - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 19 Analyst Ratings

Consensus Price Target

$426.39
22.10% Upside
High Forecast$624.00
Average Forecast$426.39
Low Forecast$310.00
TypeCurrent Forecast
5/29/23 to 5/28/24		1 Month Ago
4/29/23 to 4/28/24		3 Months Ago
2/28/23 to 2/28/24		1 Year Ago
5/29/22 to 5/29/23
Consensus Rating
Hold
Hold
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
10 Buy rating(s)
14 Buy rating(s)
Hold
10 Hold rating(s)
10 Hold rating(s)
6 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$426.39$424.50$506.72$602.44
Forecasted Upside22.10% Upside15.91% Upside19.30% Upside17.87% Upside
Get Humana Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for HUM and its competitors with MarketBeat's FREE daily newsletter.

HUM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HUM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Humana Stock vs. The Competition

TypeHumanaMedical CompaniesS&P 500
Consensus Rating Score
2.47
2.70
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside22.10% Upside831.09% Upside10.87% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Forecasts and Stock Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/20/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetNeutral ➝ Neutral$342.00 ➝ $376.00+5.56%
4/25/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform ➝ Outperform$415.00 ➝ $353.00+14.10%
4/25/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral ➝ Neutral$391.00 ➝ $360.00+16.43%
4/25/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral ➝ Neutral$334.00 ➝ $326.00+5.43%
4/25/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform ➝ Outperform$415.00 ➝ $370.00+17.07%
4/22/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$411.00 ➝ $381.00+15.74%
4/8/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight ➝ Overweight$413.00 ➝ $350.00+11.78%
4/3/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$450.00 ➝ $385.00+24.47%
4/2/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetEqual Weight ➝ Equal Weight$356.00 ➝ $310.00+0.93%
4/2/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$427.00 ➝ $396.00+32.04%
3/22/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageMarket Perform
3/13/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Hold
1/26/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$550.00 ➝ $400.00+10.46%
1/26/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight ➝ Overweight$550.00 ➝ $430.00+18.45%
1/25/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Hold$595.00 ➝ $360.00-10.54%
1/19/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingHold ➝ Hold$550.00+35.83%
11/17/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral ➝ Neutral$593.00 ➝ $575.00+13.90%
10/10/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$599.00 ➝ $579.00+15.49%
8/30/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight ➝ Overweight$637.00 ➝ $624.00+29.65%
4/27/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$640.00 ➝ $600.00+18.70%
2/6/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform$647.00 ➝ $581.00+21.91%
2/6/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform$635.00 ➝ $575.00+20.65%
11/7/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$547.00 ➝ $647.00+17.20%
11/3/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform$540.00 ➝ $640.00+14.37%
6/16/2022Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$510.00+20.47%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 07:24 PM ET.

HUM Frequently Asked Questions

What is Humana's stock forecast and purchase recommendation?

According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Humana is $426.39, with a high forecast of $624.00 and a low forecast of $310.00. The consensus rating for Humana stock is Hold based on the current 10 hold ratings and 9 buy ratings for HUM. Learn more on HUM's analyst rating history.

Do Wall Street analysts like Humana more than its competitors?

Analysts like Humana less than other "medical" companies. The consensus rating for Humana is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how HUM compares to other companies.

Is Humana being downgraded by Wall Street analysts?

Over the previous 90 days, Humana's stock had 1 downgrade by analysts.

Does Humana's stock price have much upside?

According to analysts, Humana's stock has a predicted upside of 16.34% based on their 12-month stock forecasts.

What analysts cover Humana?

Humana has been rated by research analysts at Argus, Bank of America, Barclays, Cantor Fitzgerald, Jefferies Financial Group, Oppenheimer, Raymond James, Royal Bank of Canada, TD Cowen, The Goldman Sachs Group, UBS Group, and Wells Fargo & Company in the past 90 days.


Stock Forecasts and Research Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NYSE:HUM) was last updated on 5/28/2024 by MarketBeat.com Staff

From Our Partners
WARNING about the death of the U.S. dollar…
Colonial Metals
Tim Sykes’ Urgent Trade Alert: “Make this move now”
Timothy Sykes
Elon’s New Device is About to Shock the World
InvestorPlace
Exposed: 10 CENT Crypto to Explode May 20th?
True Market Insiders
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for AI
Weiss Ratings
The #1 Crypto That You Don’t Own… Yet
Crypto 101 Media
Digitizing the $11T commodities sector with one tiny stock
Resource Stock Digest